212 related articles for article (PubMed ID: 31821176)
21. β-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites.
Frost D; Meechoovet B; Wang T; Gately S; Giorgetti M; Shcherbakova I; Dunckley T
PLoS One; 2011 May; 6(5):e19264. PubMed ID: 21573099
[TBL] [Abstract][Full Text] [Related]
22. DYRK1A phosphorylates caspase 9 at an inhibitory site and is potently inhibited in human cells by harmine.
Seifert A; Allan LA; Clarke PR
FEBS J; 2008 Dec; 275(24):6268-80. PubMed ID: 19016842
[TBL] [Abstract][Full Text] [Related]
23. Structure-Based Design and Synthesis of Harmine Derivatives with Different Selectivity Profiles in Kinase versus Monoamine Oxidase Inhibition.
Bálint B; Wéber C; Cruzalegui F; Burbridge M; Kotschy A
ChemMedChem; 2017 Jun; 12(12):932-939. PubMed ID: 28264138
[TBL] [Abstract][Full Text] [Related]
24. Discovery of novel benzothiophene derivatives as potent and narrow spectrum inhibitors of DYRK1A and DYRK1B.
Segretti ND; Takarada JE; Ferreira MA; da Silva Santiago A; Teodoro BVM; Damião MCFCB; Godoi PH; Cunha MR; Fala AM; Ramos PZ; Ishikawa EE; Mascarello A; Serafim RAM; Azevedo H; Guimarães CRW; Couñago RM
Bioorg Med Chem Lett; 2022 Jul; 68():128764. PubMed ID: 35504513
[TBL] [Abstract][Full Text] [Related]
25. A Dual Inhibitor of DYRK1A and GSK3β for β-Cell Proliferation: Aminopyrazine Derivative GNF4877.
Liu YA; Jin Q; Ding Q; Hao X; Mo T; Yan S; Zou Y; Huang Z; Zhang X; Gao W; Wu TY; Li C; Bursalaya B; Di Donato M; Zhang YQ; Deaton L; Shen W; Taylor B; Kamireddy A; Harb G; Li J; Jia Y; Schumacher AM; Laffitte B; Glynne R; Pan S; McNamara P; Molteni V; Loren J
ChemMedChem; 2020 Aug; 15(16):1562-1570. PubMed ID: 32613743
[TBL] [Abstract][Full Text] [Related]
26. Identification of a small molecule that stimulates human β-cell proliferation and insulin secretion, and protects against cytotoxic stress in rat insulinoma cells.
Hohmeier HE; Zhang L; Taylor B; Stephens S; Lu D; McNamara P; Laffitte B; Newgard CB
PLoS One; 2020; 15(3):e0224344. PubMed ID: 32176701
[TBL] [Abstract][Full Text] [Related]
27. Phosphorylation and inactivation of glycogen synthase kinase 3β (GSK3β) by dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A).
Song WJ; Song EA; Jung MS; Choi SH; Baik HH; Jin BK; Kim JH; Chung SH
J Biol Chem; 2015 Jan; 290(4):2321-33. PubMed ID: 25477508
[TBL] [Abstract][Full Text] [Related]
28. DYRK1A is a novel negative regulator of cardiomyocyte hypertrophy.
Kuhn C; Frank D; Will R; Jaschinski C; Frauen R; Katus HA; Frey N
J Biol Chem; 2009 Jun; 284(25):17320-17327. PubMed ID: 19372220
[TBL] [Abstract][Full Text] [Related]
29. Structure-Activity Relationships and Biological Evaluation of 7-Substituted Harmine Analogs for Human β-Cell Proliferation.
Kumar K; Wang P; A Swartz E; Khamrui S; Secor C; B Lazarus M; Sanchez R; F Stewart A; DeVita RJ
Molecules; 2020 Apr; 25(8):. PubMed ID: 32340326
[TBL] [Abstract][Full Text] [Related]
30. Dyrk1a haploinsufficiency induces diabetes in mice through decreased pancreatic beta cell mass.
Rachdi L; Kariyawasam D; Guez F; Aïello V; Arbonés ML; Janel N; Delabar JM; Polak M; Scharfmann R
Diabetologia; 2014 May; 57(5):960-9. PubMed ID: 24477974
[TBL] [Abstract][Full Text] [Related]
31. Neprilysin Is Suppressed by Dual-Specificity Tyrosine-Phosphorylation Regulated Kinase 1A (DYRK1A) in Down-Syndrome-Derived Fibroblasts.
Kawakubo T; Mori R; Shirotani K; Iwata N; Asai M
Biol Pharm Bull; 2017; 40(3):327-333. PubMed ID: 28250274
[TBL] [Abstract][Full Text] [Related]
32. Differential maturation and chaperone dependence of the paralogous protein kinases DYRK1A and DYRK1B.
Papenfuss M; Lützow S; Wilms G; Babendreyer A; Flaßhoff M; Kunick C; Becker W
Sci Rep; 2022 Feb; 12(1):2393. PubMed ID: 35165364
[TBL] [Abstract][Full Text] [Related]
33. Diabetic Kinome Inhibitors-A New Opportunity for β-Cells Restoration.
Pucelik B; Barzowska A; Dąbrowski JM; Czarna A
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445786
[TBL] [Abstract][Full Text] [Related]
34. DCAF7/WDR68 is required for normal levels of DYRK1A and DYRK1B.
Yousefelahiyeh M; Xu J; Alvarado E; Yu Y; Salven D; Nissen RM
PLoS One; 2018; 13(11):e0207779. PubMed ID: 30496304
[TBL] [Abstract][Full Text] [Related]
35. The small molecule harmine regulates NFATc1 and Id2 expression in osteoclast progenitor cells.
Egusa H; Doi M; Saeki M; Fukuyasu S; Akashi Y; Yokota Y; Yatani H; Kamisaki Y
Bone; 2011 Aug; 49(2):264-74. PubMed ID: 21504804
[TBL] [Abstract][Full Text] [Related]
36. How to Separate Kinase Inhibition from Undesired Monoamine Oxidase A Inhibition-The Development of the DYRK1A Inhibitor AnnH75 from the Alkaloid Harmine.
Wurzlbauer A; Rüben K; Gürdal E; Chaikuad A; Knapp S; Sippl W; Becker W; Bracher F
Molecules; 2020 Dec; 25(24):. PubMed ID: 33339338
[TBL] [Abstract][Full Text] [Related]
37. DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications.
Abbassi R; Johns TG; Kassiou M; Munoz L
Pharmacol Ther; 2015 Jul; 151():87-98. PubMed ID: 25795597
[TBL] [Abstract][Full Text] [Related]
38. Human cytomegalovirus utilises cellular dual-specificity tyrosine phosphorylation-regulated kinases during placental replication.
Hamilton ST; Hutterer C; Egilmezer E; Steingruber M; Milbradt J; Marschall M; Rawlinson WD
Placenta; 2018 Dec; 72-73():10-19. PubMed ID: 30501876
[TBL] [Abstract][Full Text] [Related]
39. A dual specificity kinase, DYRK1A, as a potential therapeutic target for head and neck squamous cell carcinoma.
Radhakrishnan A; Nanjappa V; Raja R; Sathe G; Puttamallesh VN; Jain AP; Pinto SM; Balaji SA; Chavan S; Sahasrabuddhe NA; Mathur PP; Kumar MM; Prasad TS; Santosh V; Sukumar G; Califano JA; Rangarajan A; Sidransky D; Pandey A; Gowda H; Chatterjee A
Sci Rep; 2016 Oct; 6():36132. PubMed ID: 27796319
[TBL] [Abstract][Full Text] [Related]
40. A novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in vitro.
Coutadeur S; Benyamine H; Delalonde L; de Oliveira C; Leblond B; Foucourt A; Besson T; Casagrande AS; Taverne T; Girard A; Pando MP; Désiré L
J Neurochem; 2015 May; 133(3):440-51. PubMed ID: 25556849
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
